Cargando…

Model‐Based Meta‐Analysis for Multiple Myeloma: A Quantitative Drug‐Independent Framework for Efficient Decisions in Oncology Drug Development

The failure rate for phase III trials in oncology is high; quantitative predictive approaches are needed. We developed a model‐based meta‐analysis (MBMA) framework to predict progression‐free survival (PFS) from overall response rates (ORR) in relapsed/refractory multiple myeloma (RRMM), using data...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teng, Zhaoyang, Gupta, Neeraj, Hua, Zhaowei, Liu, Guohui, Samnotra, Vivek, Venkatakrishnan, Karthik, Labotka, Richard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5867027/ https://www.ncbi.nlm.nih.gov/pubmed/29168990 http://dx.doi.org/10.1111/cts.12524

Ejemplares similares

Exposure–safety–efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study
por: Gupta, Neeraj, et al.
Publicado: (2016)

Model‐Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor
por: Gupta, Neeraj, et al.
Publicado: (2018)

Population pharmacokinetic/pharmacodynamic joint modeling of ixazomib efficacy and safety using data from the pivotal phase III TOURMALINE‐MM1 study in multiple myeloma patients
por: Srimani, Jaydeep K., et al.
Publicado: (2022)

Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011–2017: Lessons Learned for Anticancer Drug Development
por: Faucette, Stephanie, et al.
Publicado: (2017)

Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor
por: Gupta, Neeraj, et al.
Publicado: (2018)

Quantitative Translation in Immuno‐Oncology Research and Development
por: Bottino, Dean, et al.
Publicado: (2020)

A multistate modeling and simulation framework to learn dose–response of oncology drugs: Application to bintrafusp alfa in non‐small cell lung cancer
por: Liu, Han, et al.
Publicado: (2023)

Quantitative decisions in drug development
por: Chuang-Stein, Christy, et al.
Publicado: (2017)

Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma
por: Goldschmidt, Hartmut, et al.
Publicado: (2020)

Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment
por: Gupta, Neeraj, et al.
Publicado: (2016)

Diversity and Inclusion in Drug Development: Rethinking Intrinsic and Extrinsic Factors with Patient Centricity
por: Venkatakrishnan, Karthik, et al.
Publicado: (2021)

Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses
por: Gupta, Neeraj, et al.
Publicado: (2017)

Independent Drug Action in Combination Therapy: Implications for Precision Oncology
por: Plana, Deborah, et al.
Publicado: (2022)

Alternatives to rifampicin: A review and perspectives on the choice of strong CYP3A inducers for clinical drug–drug interaction studies
por: Bolleddula, Jayaprakasam, et al.
Publicado: (2022)

Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug‐Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis
por: Gupta, Neeraj, et al.
Publicado: (2017)

Asia‐Inclusive Clinical Research and Development Enabled by Translational Science and Quantitative Clinical Pharmacology: Toward a Culture That Challenges the Status Quo
por: Venkatakrishnan, Karthik, et al.
Publicado: (2022)

Physiologically‐Based Pharmacokinetic Models as Enablers of Precision Dosing in Drug Development: Pivotal Role of the Human Mass Balance Study
por: Rowland Yeo, Karen, et al.
Publicado: (2020)

Quantitative analysis on the characteristics of targets with FDA approved drugs
por: Sakharkar, Meena K., et al.
Publicado: (2007)

A Data-Driven Medical Decision Framework for Associating Adverse Drug Events with Drug-Drug Interaction Mechanisms
por: Noor, Adeeb
Publicado: (2022)

Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework
por: Paulden, Mike, et al.
Publicado: (2014)

A framework for economic evaluation of therapeutic drug monitoring—guided dosing in oncology
por: Erku, Daniel, et al.
Publicado: (2021)

The reimbursement decision speed for oncology new drugs in China and its determinant factors
por: Zhu, Xingyue, et al.
Publicado: (2023)

Rationale and proposed framework for shared decision making in cardio-oncology
por: Hull, Sarah C., et al.
Publicado: (2021)

A Causal Framework for Making Individualized Treatment Decisions in Oncology
por: Msaouel, Pavlos, et al.
Publicado: (2022)

Retracted: A Data-Driven Medical Decision Framework for Associating Adverse Drug Events with Drug-Drug Interaction Mechanisms
por: Healthcare Engineering, Journal of
Publicado: (2023)

Risk assessment of drug–drug interaction potential for bintrafusp alfa with cytochrome P4503A4 substrates: A totality of evidence approach
por: Vugmeyster, Yulia, et al.
Publicado: (2022)

A modelling framework for improved design and decision-making in drug development
por: Wiklund, Stig Johan
Publicado: (2019)

Drug Resistance in Oncology
por: Twentyman, P.R.
Publicado: (1994)

Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma
por: Kaiser, Martin, et al.
Publicado: (2020)

Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes
por: Gibson, EJ, et al.
Publicado: (2018)

Population PK and Exposure–Response Relationships for the Antibody–Drug Conjugate Brentuximab Vedotin in CTCL Patients in the Phase III ALCANZA Study
por: Suri, Ajit, et al.
Publicado: (2018)

New drugs are not enough-drug repositioning in oncology: An update
por: Armando, Romina Gabriela, et al.
Publicado: (2020)

Reliability of Oncology Value Framework Outputs: Concordance Between Independent Research Groups
por: Del Paggio, Joseph C, et al.
Publicado: (2018)

Physiologically Based Pharmacokinetic Modeling Framework for Quantitative Prediction of an Herb–Drug Interaction
por: Brantley, S J, et al.
Publicado: (2014)

Oncology Drug Shortages in America
por: Vogel, Wendy H., et al.
Publicado: (2012)

Innovation in Oncology Drug Development
por: Huber, Matthew, et al.
Publicado: (2019)

A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end‐stage renal disease requiring haemodialysis
por: Gupta, Neeraj, et al.
Publicado: (2016)

A comparison of the Food and Drug Administration’s and Health Canada’s regulatory decisions about failed confirmatory trials for oncology drugs: an observational study
por: Lexchin, Joel
Publicado: (2021)

Cancer drug resistance in multiple myeloma
por: Uckun, Fatih M.
Publicado: (2022)

Quantitative Framework for Retrospective Assessment of Interim Decisions in Clinical Trials
por: Stanev, Roger
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_qik5nt5p6ur6t9r4275cnvdboq